Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Date:5/21/2013

change rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; including without limitation dupilumab; unforeseen safety issues resulting from the administration of products and product candidates in patients; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
2. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
3. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
4. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
5. NextBio Announces Translational Medicine Partnership with Sanofi
6. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
7. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
8. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
9. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... 11, 2014 Alliance for Cancer ... non-profit dedicated exclusively to cell and gene therapies ... has joined the organization as Senior Development Officer. ... deep experience securing gifts and addressing influential donors. ... Giving Director for NewYork Presbyterian Hospital/Columbia University Medical ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... July 11, 2014 Presently, disposable medical ... healthcare equipment and supplies segment. During the past two ... steady growth (on an average 12.5% per year), primarily ... settings. Currently, the US is the largest market for ... share of 40%. The second position is held by ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Enjoy the Freedom to Breathe, Event to Raise Awareness of Benefits ... ... Hundreds of attendees,of this week,s 2007 National Conference on Tobacco or ... Thursday outside,the Minneapolis Convention Center to raise awareness about the benefits ...
... Open Access: freely available for anyone to read, ... the authorship is properly attributed. , This week ... that aim to highlight the profound influence of ... of Science Editors Global Theme Issue on Poverty ...
... Care Pipeline Offers State-of-the-art Treatment, MEMPHIS, ... leader in cancer care, announced today the ... square foot, state-of-the art,facility is being opened ... provide ,western-style, comprehensive cancer care. Shanghai,represents the ...
... of gloss, depth of image, and ... MANSFIELD, Texas, Oct. 22 Solvay Engineered Polymers,Inc., ... use in the,production of extruded sheet. The new ... acrylic layer onto a substrate of thermoplastic,polyolefin (TPO) ...
... and NEW YORK, Oct. 22 ,Genzyme Corporation (Nasdaq: ... BIVN ),announced this afternoon that Bioenvision stockholders have ... Genzyme at a reconvened special,shareholder meeting in New ... have now ceased trading and the company will,be ...
... ,Super Bug, Other Biological ... ... dozens of cases of MRSA,the drug-resistant staph bacterium, are being reported ... student, some,school districts are taking the proactive step of bringing in ...
Cached Medicine News:Health News:Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air 2Health News:Which intervention would do the most to improve the health of the extreme poor? 2Health News:Which intervention would do the most to improve the health of the extreme poor? 3Health News:Which intervention would do the most to improve the health of the extreme poor? 4Health News:Which intervention would do the most to improve the health of the extreme poor? 5Health News:West Clinic Continues Expansion Into Asian Market With Opening of Shanghai Cancer Center 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:MARCOR Responds to Deadly MRSA Outbreak 2
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Medicine Products: